NSCLC - Efti+ pembro(stage1, Part A): 53% iORR PD-L1 all-comer+ medianPFS expected 9+ mts
Historical data above may improve further - which has been seen in other trials.
I think Merck would be delighted with current status and PFS > 9 months
HNSCC - Efti+ pembro (stage1, Part C): 39% iORRin PD-L1 all-comerincl. 1 iCR(6 %); 50 % DCR
Pembro mono - iORR - only 16%
Ditto above. This may be the first cab for a licensing deal with Merck.....awaiting Snowy's BOOM!
"Efti could address unmet medical needs in 2ndline HNSCC offering a potential pathway to early regulatory interactions (registration)"
ESMO, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.138M | 3.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63444 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 65000 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |